Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Results of a Phase 3 Randomised Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Not Eligible for Stem Cell Transplantation

Gilles Andre Salles, Wojciech Jurczak, David J. Andorsky, MD, Donald P. Quick, MD, Jack W. Singer, MD, Simran Bedi Singh, Lixia Wang, PhD, Anton Egorov, MD, Christine Gabarroca, MSc, Ruth Pettengell, MD

Blood (2018) 132 (Supplement 1): 4189.

https://doi.org/10.1182/blood-2018-99-112455

Published: 2018

Journal Articles

Pooled Analyses of Total Symptom Score (TSS) Responses in Patients with Myelofibrosis (MF) Treated with Pacritinib (PAC) Vs Best Available Therapy (BAT) in Phase 3 Studies (PERSIST-1, PERSIST-2)

Ruben A. Mesa, MD FACP, Francisco Cervantes, MD PhD, Claire N. Harrison, MD DM, FRCP, PRCPath, Adam J. Mead, MD PhD, Alessandro M. Vannucchi, MD, Srdan Verstovsek, MD PhD, Lixia Wang, PhD, Tanya Granston, PhD, John Mascarenhas, MD

Blood (2018) 132 (Supplement 1): 4281.

https://doi.org/10.1182/blood-2018-99-114779

Published: 2018

Journal Articles

Statins Potentiate Aminopeptidase Inhibitor (pro)Drug Activity in Acute Myeloid Leukemia Cells

Jacqueline Cloos, PhD, Godefridus J Peters, PhD, Marjon Al, BSc, Yehuda G Assaraf, PhD, Lixia Wang, PhD, Jack W. Singer, MD, Jorge E. Cortes, MD, Gert J. Ossenkoppele, MD PhD, Gerrit Jansen, PhD

Blood (2018) 132 (Supplement 1): 3945.

https://doi.org/10.1182/blood-2018-99-114447

Published: 2018

Journal Articles

Quantitative Testing of the Myelofibrosis Symptom Assessment Form Version 4.0, a Harmonized Patient-Reported Outcome Measure for Collecting Key Secondary Endpoint Data in Myelofibrosis Clinical Trials

Amylou C. Dueck, PhD, Chad Gwaltney, PhD, Wen-Hung Chen, PhD, Lixia Wang, PhD, Renee Pierson, MBA, Jeremiah Trudeau, PhD, Sonya Eremenco, MA, Stephen Joel Coons, PhD, Ruben A Mesa, MD

Blood (2017) 130 (Supplement 1): 2168.

https://doi.org/10.1182/blood.V130.Suppl_1.2168.2168

Published: 2017

Journal Articles

A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Raya Mawad, MD, Pamela S. Becker, MD PhD, Paul C. Hendrie, MD PhD, Bart L Scott, MD, Brent L. Wood, MD PhD, Carol Dean, MPH, BSN, Vicky Sandhu, MD MPH, H. Joachim Deeg, MD, Roland B. Walter, MD PhD MS, Lixia Wang, PhD, Jack Singer, MD, Elihu H. Estey, MD, John Pagel, MD PhD

Blood (2014) 124 (21): 3690.

https://doi.org/10.1182/blood.V124.21.3690.3690

Published: 2014

Journal Articles

Exposure-Response Analysis For Pacritinib (SB1518), a Novel Oral JAK2/FLT3 Inhibitor, In Patients With Myelofibrosis

Suliman Al-Fayoumi, PhD, MBA, Lixia Wang, PhD, Hanbin Li, PhD, Russ Wada, PhD, James P. Dean, MD, PhD

Blood (2013) 122 (21): 4080.

https://doi.org/10.1182/blood.V122.21.4080.4080

Published: 2013

Journal Articles

A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS)

Raya Mawad, MD, Pamela S. Becker, MD, PhD, Paul C. Hendrie, MD, PhD, Bart L Scott, MD, Brent L. Wood, MD, PhD, Carol Dean, RN, Ravinder K Sandhu, MD, H. Joachim Deeg, MD, Roland B. Walter, MD, PhD, Frederick R. Appelbaum, MD, Lixia Wang, PhD, Han Myint, MD, Jack Singer, MD, Elihu H. Estey, MD, John M. Pagel, MD, PhD

Blood (2013) 122 (21): 3926.

https://doi.org/10.1182/blood.V122.21.3926.3926

Published: 2013

Journal Articles

Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis (MF) and Platelet Counts ≤100,000/µl

Srdan Verstovsek, MD, PhD, James P. Dean, MD, PhD, Paul Cernohous, MS, Rami S Komrokji, MD, John F. Seymour, MBBS, FRACP, PhD, Ruben A. Mesa, MD, Mary S Campbell, MD, Susan E. Caldwell, PhD, Lixia Wang, PhD, Han Myint, MD

Blood (2013) 122 (21): 395.

https://doi.org/10.1182/blood.V122.21.395.395

Published: 2013

Journal Articles

Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results.

Ruth Pettengell, FRACP, PhD, Pier Luigi Zinzani, MD, PhD, Geetha Narayanan, MD, Fernando Hurtado de Mendoza, MD, Raghunadharao Digumarti, MD, Henry Gomez, MD, Bertrand Coiffier, MD, PhD, Gary Schiller, MD, David A. Rizzieri, MD, Paul Cernohous, MS, Lixia Wang, PhD, Jack Singer, MD

Blood (2010) 116 (21): 2833.

https://doi.org/10.1182/blood.V116.21.2833.2833

Published: 2010

Journal Articles

Pixantrone Dimaleate (PIX) and Comparators In the Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (aNHL): An Analysis of Response and Survival by Gender and Age

Jack Singer, MD, Paul Cernohous, MS, Gabor Jurida, MD, Lixia Wang, PhD, Christine Kuepfer, MS, Ruth Pettengell, FRACP, PhD

Blood (2010) 116 (21): 4883.

https://doi.org/10.1182/blood.V116.21.4883.4883

Published: 2010

NARROW

Results of a Phase 3 Randomised Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Not Eligible for Stem Cell Transplantation

Pooled Analyses of Total Symptom Score (TSS) Responses in Patients with Myelofibrosis (MF) Treated with Pacritinib (PAC) Vs Best Available Therapy (BAT) in Phase 3 Studies (PERSIST-1, PERSIST-2)

Statins Potentiate Aminopeptidase Inhibitor (pro)Drug Activity in Acute Myeloid Leukemia Cells

Quantitative Testing of the Myelofibrosis Symptom Assessment Form Version 4.0, a Harmonized Patient-Reported Outcome Measure for Collecting Key Secondary Endpoint Data in Myelofibrosis Clinical Trials

A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Exposure-Response Analysis For Pacritinib (SB1518), a Novel Oral JAK2/FLT3 Inhibitor, In Patients With Myelofibrosis

A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS)

Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis (MF) and Platelet Counts ≤100,000/µl

Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results.

Pixantrone Dimaleate (PIX) and Comparators In the Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (aNHL): An Analysis of Response and Survival by Gender and Age

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only